Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

NCT03283137 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

CLL
B-cell Non Hodgkin Lymphoma

Interventions

DRUG: TGR-1202
DRUG: Pembrolizumab

Sponsor

University of Chicago